Hinta Meijerink
Overview
Explore the profile of Hinta Meijerink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
520
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Soares P, Machado A, Nicolay N, Monge S, Sacco C, Holm Hansen C, et al.
Euro Surveill
. 2025 Feb;
30(8).
PMID: 40017392
BackgroundDuring the first year of the COVID-19 pandemic, vaccination programmes targeted children and adolescents to prevent severe outcomes of SARS-CoV-2 infection.AimTo estimate COVID-19 vaccine effectiveness (VE) against hospitalisation due to...
2.
Hansen B, Klungsoyr O, Labberton A, Saaksvuori L, Rydland K, Odeskaug L, et al.
JMIR Res Protoc
. 2025 Feb;
14:e63938.
PMID: 39998878
Background: The coverage of influenza vaccination among older adults in Norway is insufficient, especially in some immigrant groups. To improve public health, there is a need for an intervention that...
3.
Nunes B, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, et al.
Expert Rev Vaccines
. 2024 Nov;
23(1):1085-1090.
PMID: 39535047
Background: We aimed to estimate XBB.1.5 vaccine effectiveness (VE) against COVID-19-related hospitalizations and deaths during BA.2.86/JN.1 predominance, among EU/EEA individuals with ≥65-years. Research Design And Methods: We linked electronic health...
4.
Mesle M, Brown J, Mook P, Katz M, Hagan J, Pastore R, et al.
Lancet Respir Med
. 2024 Aug;
12(9):714-727.
PMID: 39127051
Background: By March, 2023, 54 countries, areas, and territories (hereafter CAT) in the WHO European Region had reported more than 2·2 million COVID-19-related deaths to the WHO Regional Office for...
5.
Meijerink H, Veneti L, Kristoffersen A, Danielsen A, Stecher M, Starrfelt J
BMC Public Health
. 2024 Jul;
24(1):1861.
PMID: 38992631
Background: Due to changes in testing policy and increased use of rapid tests, other indicators for SARS-CoV-2 infections are needed to monitor vaccine effectiveness (VE). We aimed to estimate VE...
6.
Engjom H, Skar F, Meijerink H, Bakken I, Halvorsen G, Dvergsdal E, et al.
Tidsskr Nor Laegeforen
. 2024 Jun;
144(7).
PMID: 38832619
No abstract available.
7.
Monge S, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, et al.
Influenza Other Respir Viruses
. 2024 Apr;
18(4):e13292.
PMID: 38654485
Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in booster-eligible ≥ 65-year-olds, during...
8.
Meijerink H, Shelil M, Jani-Bolstad J, Dvergsdal E, Madslien E, Wilberg M, et al.
BMC Health Serv Res
. 2024 Jan;
24(1):96.
PMID: 38233812
Background: During the COVID-19 response in Norway, many municipalities used the Fiks contact tracing tool (FiksCT) to register positive individuals and follow-up contacts. This tool is based on DHIS2, an...
9.
Poukka E, Andersson N, Thiesson E, Baum U, Pihlstrom N, Perala J, et al.
Pediatrics
. 2024 Jan;
153(2).
PMID: 38196395
Background: For adolescents, data on the long-term effectiveness of the BNT162b2 and mRNA-1273 vaccines against severe COVID-19 outcomes are scarce. Additionally, only a few studies have evaluated vaccine effectiveness (VE)...
10.
Fontan-Vela M, Kissling E, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, et al.
Euro Surveill
. 2024 Jan;
29(1).
PMID: 38179626
To monitor relative vaccine effectiveness (rVE) against COVID-19-related hospitalisation of the first, second and third COVID-19 booster (vs complete primary vaccination), we performed monthly Cox regression models using retrospective cohorts...